Cutler Group LP Editas Medicine, Inc. Put Options Transaction History

Cutler Group LP

16 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2022 Aug 04, 2022	SELL	$9.99 - $21.35 $9,990 - $21,350	-1,000 Reduced 71.43%	400 $19,000
Q1 2022 Apr 14, 2022	SELL	$14.08 - $27.63 $698,368 - $1.37 Million	-49,600 Reduced 97.25%	1,400 $16,000
Q4 2021 Jan 18, 2022	BUY	$26.55 - $40.57 $475,245 - $726,203	17,900 Added 54.08%	51,000 $124,000
Q3 2021 Oct 26, 2021	BUY	$39.27 - $72.94 $1.26 Million - $2.34 Million	32,100 Added 3210.0%	33,100 $96,000
Q2 2021 Jul 19, 2021	BUY	$31.29 - $56.64 $18,774 - $33,984	600 Added 150.0%	1,000 $13,000
Q1 2021 Apr 26, 2021	SELL	$39.71 - $90.58 $3,971 - $9,058	-100 Reduced 20.0%	400 $12,000
Q4 2020 Jan 21, 2021	SELL	$27.07 - $84.35 $54,140 - $168,700	-2,000 Reduced 80.0%	500 $11,000
Q4 2019 Feb 06, 2020	SELL	$19.49 - $32.63 $31,183 - $52,208	-1,600 Reduced 39.02%	2,500 $0
Q3 2019 Oct 28, 2019	SELL	$22.49 - $26.81 $4,498 - $5,362	-200 Reduced 4.65%	4,100 $38,000
Q2 2019 Aug 09, 2019	BUY	$20.48 - $27.76 $4,096 - $5,552	200 Added 4.88%	4,300 $36,000
Q1 2019 May 10, 2019	SELL	$19.43 - $26.41 $108,808 - $147,896	-5,600 Reduced 57.73%	4,100 $39,000
Q3 2018 Nov 07, 2018	SELL	$27.65 - $38.39 $143,780 - $199,628	-5,200 Reduced 34.9%	9,700 $30,000
Q2 2018 Aug 10, 2018	BUY	$31.4 - $41.01 $37,680 - $49,212	1,200 Added 8.76%	14,900 $42,000
Q1 2018 May 11, 2018	SELL	$29.84 - $44.08 $468,488 - $692,056	-15,700 Reduced 53.4%	13,700 $59,000
Q4 2017 Jan 17, 2018	BUY	$21.89 - $31.34 $295,515 - $423,090	13,500 Added 84.91%	29,400 $84,000
Q3 2017 Oct 17, 2017	BUY	$15.81 - $24.01 $251,379 - $381,759	15,900	15,900 $26,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.